Trial Profile
An open label, prospective, multicenter, single-arm clinical trial to investigate the safety and the analgesic effectiveness of a low dose (4 mg) OROS hydromorphone hydrochloride as starting dose in opioid-nave patients with cancer pain
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 03 Feb 2014
Price :
$35
*
At a glance
- Drugs Hydromorphone (Primary)
- Indications Cancer pain
- Focus Adverse reactions
- Sponsors Janssen-Cilag
- 03 Feb 2014 New trial record